FIELD: molecular biology.
SUBSTANCE: invention relates to the field of molecular biology and can be used for the differential diagnosis of brain glial tumors of high grades of malignancy. A method for the differential diagnosis of high-grade gliomas is described, in which total RNA is isolated from a glioma tissue sample, the synthesis of the 1st strand of cDNA is carried out using a reverse transcription reaction, real-time PCR is performed with primers matched to the mRNA of the TEK, C3, MKI67, HIF1A genes, OLIG2, TNFRSF1A. The degree of malignancy of glioma "y" is calculated by the formula: у=1,69-2,844×X1-0.883×X2-0.043×X3+0.081×X4+0.169×X5-0.04×X6, where X1 - TEK gene expression; X2 - expression of the C3 gene; X3 - MKI67 gene expression; X4 - HIF1A gene expression; X5 - expression of the OLIG2 gene; X6 - TNFRSF1A gene expression. If the values of "y" are greater than 2.4, but less than 3.4, the tumor is classified as Grade III; with "y" greater than 3.4, the diagnosis is "glioblastoma", Grade IV.
EFFECT: increasing the accuracy of the method, reducing labor intensity and simplifying it.
1 cl, 1 dwg, 1 ex
Title | Year | Author | Number |
---|---|---|---|
METHOD FOR ASSESSING CELL MALIGNANCY IN GLIOMA CULTURES | 2022 |
|
RU2786007C1 |
METHOD FOR ESTIMATING THE DEGREE OF CELL ANAPLASIA IN THE GLIOMA CULTURE | 2021 |
|
RU2780236C1 |
METHOD OF DIFFERENTIAL DIAGNOSIS OF GLIAL BRAIN TUMORS | 2020 |
|
RU2743223C1 |
METHOD FOR DIFFERENTIAL DIAGNOSIS OF GLIOMAS OF HUMAN BRAIN | 2015 |
|
RU2583871C1 |
METHOD FOR DIFFERENTIAL DIAGNOSIS OF GLIOMAS BASED ON ANALYSIS OF GENE EXPRESSION AND MICRO-RNA | 2018 |
|
RU2709651C1 |
METHOD FOR PREDICTION OF LYMPHATIC METASTASIS IN COLON ADENOCARCINOMA | 2019 |
|
RU2688678C1 |
METHOD OF PREDICTING HEMATOGENOUS METASTASIS OF COLON CANCER AFTER COMBINED TREATMENT | 2023 |
|
RU2797845C1 |
METHOD FOR DIAGNOSING GLIAL BRAIN TUMORS OF HIGH DEGREE OF MALIGNANCY | 2020 |
|
RU2742413C1 |
METHOD FOR PREDICTION OF EVOLUTION OF CEREBRAL GLIOMAS | 2020 |
|
RU2740194C1 |
METHOD FOR PREDICTION OF FULL REGRESSION PROBABILITY DURING NEOADJUVANT CHEMOTHERAPY IN PATIENTS WITH THREE-TIMES NEGATIVE MOLECULAR-GENETIC SUBTYPE OF BREAST CANCER | 2016 |
|
RU2623118C1 |
Authors
Dates
2022-12-15—Published
2022-04-27—Filed